# US 2025/0360097 A2 · Treprostinil for the treatment of pulmonary hypertension

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0360097 A2
- Document ID: US20250360097A2
- Status: Published application
- Kind: A2
- Application number: 18/730,325
- Filed: 2023-01-18
- Published: 2025-11-27
- Earliest claimed: 2022-01-21
- Assignees: Invox Belgium NV
- Applicants: invoX Belgium NV
- Inventors: Isabel d’Orey Marchand Sequeira Lopes Beirão Belo; Juergen Rawert
- Web page: https://patentgrep.com/patent/US20250360097A2

## CPC

- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/5575: having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
- A61K 9/0078: {for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61M 11/007: {Syringe-type or piston-type sprayers or atomisers}
- A61M 15/0003: {with means for dispensing more than one drug}
- A61M 15/0066: {with means for varying the dose size}
- A61P 11/00: Drugs for disorders of the respiratory system
- A61M 11/005: {using ultrasonics (spraying or atomising liquids using ultrasonic vibrations in general B05B17/06)}
- A61M 15/0085: {using ultrasonics (spraying or atomising liquids using ultrasonic vibrations in general B05B17/06)}
- A61M 15/009: {using medicine packages with incorporated spraying means, e.g. aerosol cans (pocket atomiser of the injector type A61M11/08)}
- A61M 2202/0468: non-physiological
- A61M 2205/123: with incorporated reservoirs
- A61M 2206/16: Rotating swirling helical flow, e.g. by tangential inflows
- A61M 2209/02: Equipment for testing the apparatus
- A61M 2209/06: Packaging for specific medical equipment
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Treprostinil or a pharmaceutically acceptable salt or derivative thereof may be used in treating pulmonary hypertension in a subject at risk of developing pulmonary hypertension. The treatment may include administering to the subject a first liquid composition comprising Treprostinil or a pharmaceutically acceptable salt or derivative thereof in a first concentration in aerosolized form for a first treatment period, and administering to said subject a second liquid composition comprising Treprostinil or a pharmaceutically acceptable salt or derivative thereof in a second concentration in aerosolized form for a second treatment period following the first treatment period. The second concentration of the second liquid composition may be higher than the first concentration in the first liquid composition. The liquid compositions are administered using a soft mist inhaler.

## Claims

### Claim 1

A method of treating or preventing pulmonary hypertension in a subject, the method comprising:
i) administering to said subject a first liquid composition comprising Treprostinil or a pharmaceutically acceptable salt or derivative thereof in a first concentration in aerosolized form for a first treatment period, and
ii) administering to said subject a second liquid composition comprising Treprostinil or a pharmaceutically acceptable salt or derivative thereof in a second concentration in aerosolized form for a second treatment period following the first treatment period;
wherein the second concentration of Treprostinil or a pharmaceutically acceptable salt or derivative thereof in the second liquid composition is higher than the first concentration of Treprostinil or a pharmaceutically acceptable salt or derivative thereof in the first liquid composition, and
wherein the first and the second liquid compositions are aerosolized and administered to the subject using a soft mist inhaler.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The method of treatment of claim 1, further comprising:
iii) administering a third liquid composition comprising Treprostinil or a pharmaceutically acceptable salt or derivative thereof in a third concentration in aerosolized form for a third treatment period following the second treatment period;
wherein the third concentration of Treprostinil or a pharmaceutically acceptable salt or derivative thereof in the third liquid composition is higher than the second concentration of Treprostinil or a pharmaceutically acceptable salt or derivative thereof in the second liquid composition, and
wherein the third liquid composition is aerosolized and administered to the subject using a soft mist inhaler.

### Claim 4 (depends on 1)

The method of treatment of claim 1, wherein the concentration of Treprostinil or a pharmaceutically acceptable salt or derivative thereof in the first liquid composition ranges from about 1 mg/mL to about 3 mg/mL.

### Claim 5 (depends on 1)

The method of treatment of claim 1, wherein the concentration of Treprostinil or a pharmaceutically acceptable salt or derivative thereof in the second liquid composition ranges from about 2 mg/mL to about 4 mg/mL.

### Claim 6 (depends on 3)

The method of treatment of claim 3, wherein the concentration of Treprostinil or a pharmaceutically acceptable salt or derivative thereof in the third liquid composition ranges from about 3 mg/mL to about 6 mg/mL.

### Claim 7 (depends on 3)

The method of treatment of claim 3, wherein each of the first, the second and the third liquid composition is an aqueous solution comprising an aqueous solvent or mixture of solvents.

### Claim 8 (depends on 3)

The method of treatment of claim 3, wherein the first, the second and the third liquid composition further comprises one or more pharmaceutically acceptable excipients.

### Claim 9 (depends on 1)

The method of treatment of claim 1, wherein the duration of the first treatment period ranges from about 1 day to about 15 days.

### Claim 10 (depends on 1)

The method of treatment of claim 1, wherein the duration of the second treatment period ranges from about 1 day to about 15 days.

### Claim 11 (depends on 1)

The method of treatment of claim 1, wherein the amount of Treprostinil or a pharmaceutically acceptable salt or derivative thereof administered in a single event during the first treatment period ranges from about 10 μg to about 25 μg.

### Claim 12 (depends on 1)

The method of treatment of claim 1, wherein the amount of Treprostinil or a pharmaceutically acceptable salt or derivative thereof administered in a single event during the second treatment period ranges from about 25 μg to about 50 μg.

### Claim 13 (depends on 3)

The method of treatment of claim 3, wherein the amount of Treprostinil or a pharmaceutically acceptable salt or derivative thereof administered in a single event during the third treatment period ranges from about 40 μg to about 70 μg.

### Claim 14 (depends on 3)

The method of treatment of claim 3, further comprising administering a single metered dose of Treprostinil or a pharmaceutically acceptable salt or derivative thereof in a single event during the first, second and third treatment period in one breath each upon a single activation of the soft mist inhaler.

### Claim 15 (depends on 1)

The method of treatment of claim 1, wherein Treprostinil or a pharmaceutically acceptable salt or derivative thereof is administered to the subject during the first treatment period in a daily dose from about 40 μg to about 100 μg.

### Claim 16 (depends on 1)

The method of treatment of claim 1, wherein Treprostinil or a pharmaceutically acceptable salt or derivative thereof is administered to the subject during the second treatment period in a daily dose ranging from about 100 μg to about 200 μg.

### Claim 17

(canceled)

### Claim 18 (depends on 3)

The method of treatment of claim 3, wherein Treprostinil or a pharmaceutically acceptable salt or derivative thereof in the first, the second and the third liquid composition is Treprostinil sodium.

### Claim 19 (depends on 3)

The method of treatment of claim 3, wherein the soft mist inhaler is adapted to generate an aerosol or plume of aerosol of the first, second and third liquid composition having an average velocity of 1.0 to 2.5 m/s.

### Claim 20

(canceled)

### Claim 21 (depends on 3)

The method of treatment of claim 3, wherein the soft mist inhaler is adapted to aerosolize the first, second and optional third liquid composition comprising Treprostinil or a pharmaceutically acceptable salt or derivative thereof by an entirely mechanical mechanism.

### Claim at position 22

22-23. (Canceled)

### Claim 24 (depends on 3)

The method of treatment of claim 3, wherein the soft mist inhaler is an impingement-type soft mist inhaler having at least one nozzle with at least two ejection channels adapted to generate at least two jets of the first, second and optional third liquid composition comprising Treprostinil or a pharmaceutically acceptable salt or derivative thereof that intersect to generate an aerosol.

### Claim 25 (depends on 1)

The method of treatment of claim 1, wherein the soft mist inhaler is a hand-held inhalation device for delivering a nebulised medically active aerosol for inhalation therapy, comprising
(a) a housing having a user-facing side;
(b) an impingement-type nozzle for generating the nebulised aerosol by collision of at least two liquid jets, the nozzle being firmly affixed to the user-facing side of the housing such as to be immobile relative to the housing;
(c) a fluid reservoir arranged within the housing; and
(d) a pumping unit arranged within the housing, the pumping unit having
an upstream end that is fluidically connected to the fluid reservoir;
a downstream end that is fluidically connected to the nozzle;
wherein the pumping unit is adapted for pumping fluid from the fluid reservoir to the nozzle;
wherein the pumping unit further comprises
(i) a riser pipe having an upstream end, wherein the riser pipe is
adapted to function as a piston in the pumping unit, and
firmly affixed to the user-facing side of the housing such as to be immobile relative to the housing; and
(ii) a hollow cylinder located upstream of the riser pipe, wherein the upstream end of the riser pipe is inserted in the cylinder such that the cylinder is longitudinally movable on the riser pipe;
(iii) a lockable means for storing potential energy when locked and for releasing the stored energy when unlocked, the means being arranged outside of, and mechanically coupled to, the cylinder such that unlocking the means results in a propulsive longitudinal movement of the cylinder towards the downstream end of the pumping unit.

### Claim at position 25

26-35. (canceled)
